3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
Recruiting · NCT06205992 · Observational (researchers observe without assigning treatment) · Lead sponsor: Shengjing Hospital
View the official record on ClinicalTrials.gov →Interventions studied
2D-MRE3D-MREHVPG
What this trial is about
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis. We plan to compare the ability of three demensional-magnetic resonance elastography (3D-MRE) to two demensional-magnetic resonance elastography (2D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- age \> 18 years old
- confirmed cirrhosis (laboratory, imaging and clinical symptoms)
- with 3D-MRE and 2D-MRE within 1 month prior to HVPG measurement
- written informed consent
Exclusion criteria
- any previous liver or spleen surgery
- liver cancer; chronic acute liver failure
- acute portal hypertension
- unreliable HVPG, 3D-MRE or 2D-MRE results due to technical reasons
- with liver interventional therapy between HVPG and MRE
Where it is running
1 location listed.
- Shengjing Hospital of China Medical University - Shenyang, Liaoning, China